Become a DETERMINE partner
DETERMINE is the first UK national precision medicine trial in rare cancers
The DETERMINE trial enables the valuation of licensed targeted cancer drugs in unlicensed cancer indications. We are seeking additional licensed targeted drugs from pharmaceutical and biotech companies and welcome enquiries about being included in the study.
The trial is expected to recruit for 5 years with a 2-year follow-up period. Treatment arms will be added on a continual basis, with each arm to be evaluated through regular interim analyses.
As a commercial partner, you’ll benefit from:
- novel, fast-track route to approval via the Cancer Drugs Fund (CDF) for drugs which prove effective
- rich translational data package that can help optimise biomarker selection of patients
- streamlined compassionate use requests into a structured access mechanism with associated data collection
- dedicated Business Development contact and single contract to gain access to a trial with over 20 sites
What to expect
More about DETERMINE
To enter the DETERMINE trial, drugs must target a genomic aberration detectable by genetic screening, be licensed in a major market (eg MHRA, FDA, EMA), and have a UK/EU-compliant drug supply mechanism.
Current treatment arms
There are currently 7 agents available across 5 arms in the DETERMINE trial, each targeting a specific genomic profile:
- Alectinib (Alecensa)
- Atezolizumab (Tecentriq)
- Entrectinib (Rozlytrek)
- Trastuzumab (Herceptin) and Pertuzumab (Perjeta)
- Vemurafenib (Zelboraf) and Cobimetinib (Cotellic)
Recruitment and delivery
The trial aims to recruit 800-900 patients, through existing national screening programmes over the 5-year recruitment period.
DETERMINE will be delivered through the Experimental Cancer Medicine Centres Network, which consists of 29 adult and paediatric sites across the UK.
As the trial sponsor, the Cancer Research UK Centre for Drug Development is responsible for all aspects of management and delivery of DETERMINE, acting as the central contact point for our partners.
Our partners
Roche
Founding pharma partner Roche Products Ltd (UK) joined us in December 2021. Roche is providing funding, drug and genomics tests for the initial five treatment arms in this study. They have provided seven of their targeted therapies to be evaluated.
Novartis
Novartis joined us as our second partner in December 2022.
They have provided one therapy as part of the trial.
Other things you may be interested in
PRIME-ROSE
PRIME-ROSE aims to broaden patient access to a wider range of innovative precision cancer medicine treatments by connecting similar clinical trials.
Centre for Drug Development (CDD)
CDD partners with academics, biotech, and pharma to deliver early-phase clinical trials.
Experimental Cancer Medicine Centres Network (ECMC)
The ECMC network supports Cancer Research UK, industry, other funders and partners with early phase trials.